Amyloidosis

Midwest CEPAC
September 13, 2018 9am- 5pm CT

Chicago Marriott at Medical District/UIC

625 S Ashland Ave

Chicago, IL 60607

The Midwest CEPAC deliberated and voted on ICER's report on treatments for hereditary transthyretin-related (hATTR) amyloidosis, a rare genetic condition characterized by nerve, heart, and eye damage that is currently treated through supportive measures alone. The Council also reviewd a report on therapies for prostate cancer during this meeting.

Key Dates

Associated Materials

02/16/2018 – 03/07/2018
Open Input Period

03/12/2018

Open to public comment until April 2, 2018. Click here for more information on submitting a public comment, please visit our stakeholder engagement page.


03/12/2018

03/12/2018 – 04/02/2018